Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage ...

(RTTNews) - Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, Tuesday reported positive topline data from its Phase 1 studies of PALI-2108, which is being developed for the ...

Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio ...

Earnings Estimate Revisions for Palisade Bio This company is expected to earn -$11.40 per share for the fiscal year ending December 2024, which represents a year-over-year change of 57.8%.

Palisade Bio Q1 EPS $(4.59) Misses $(4.28) Es ...

Palisade Bio's stock saw a surge in volume, trading at 26.97M shares, far exceeding its 107.68k average, with no news cited for the rise. Phase 1 study shows PALI-2108 is safe at 15mg-150mg doses ...

Palisade Bio is fortifying its brand image. The California-based biotech unveiled a new logo and website design, while also doubling down on its commitment to advancing its lead candidate in ...

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes ...

Based on these results, Palisade Bio plans to initiate an additional safety and tolerability and PK/PD exploration Phase 1b cohort in FSCD while completing longer-term chronic safety and ...

Based on these results, Palisade Bio plans to initiate an additional safety and tolerability and PK/PD exploration Phase 1b cohort in FSCD while completing longer-term chronic safety and ...